To investigate the role of CD27 in multiple myeloma(MM), bone marrow samples from 165 newly diagnosed MM were analysed by flow cytometry. CD27- group (n = 93) had higher level of plasma cell proportion (37.00% vs 22.50%, p < .05), β2-MG (5.42 vs 3.20 mg/L, p < .05), calcium (2.45 vs 2.28 mmol/L, p < .05),higher percentage of ISS stage III (49.46% vs 22.22%, p < .05) and patients with ≥2 high-risk cytogenetics (24.73% vs 15.28%, p < .05) than CD27+ group (n = 72). After 4 cycles of chemotherapy, the overall response rate in CD27- group were lower than CD27+ group (56.67% vs 73.02%,p < .05). After a median follow-up of 18 months，progression-free survival was significantly shorter in CD27- group than in CD27+ group (22 vs 40 months, p < .05), so was overall survival (median OS not reached, p < .05). Gene sequencing showed more adverse mutations in CD27- group than CD27+ group.

中文翻译：

---

CD27抗原阴性表达表明新诊断的多发性骨髓瘤预后不良。

为了研究CD27在多发性骨髓瘤（MM）中的作用，通过流式细胞术分析了165例新诊断的MM的骨髓样本。CD27-组（n = 93）的浆细胞比例较高（37.00％对22.50％，p <.05），β2-MG（5.42对3.20 mg / L，p <.05），钙（2.45对2.28） mmol / L，p <.05），ISS III期百分比更高（49.46％vs 22.22％，p <.05）和≥2高细胞遗传学患者（24.73％vs 15.28％，p <.05） CD27 +组（n = 72）。经过4个周期的化疗，CD27-组的总缓解率低于CD27 +组（56.67％vs 73.02％，p <.05）。中位随访18个月后，CD27-组的无进展生存期明显短于CD27 +组（22 vs 40个月，p <.05），总体生存期也未达到中位OS（p <。 05）。